Articles related to STEM CELLS

Primary care physicians are crucial in managing the intricate health complications of allogeneic HCT survivors, including chronic graft-vs-host disease and increased cardiovascular risks.

Explore the latest insights into the complex pathophysiology of steroid-refractory cGVHD and the significant strides made in treatment options, including the impactful roles of ruxolitinib, belumosudil, and ibrutinib in enhancing patient outcomes.

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.

This recent development regarding survival rates in the study underscores the complexity and challenges in developing effective treatments for ALS.

We invite you to learn more about this groundbreaking stem cell therapy for Parkinson’s disease. This patented method holds great promise and could potentially revolutionize how we treat this debilitating condition.